Business Context and Reporting Period
Company: Klotho Neurosciences, Inc. (formerly ANEW Medical, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: The Company is a pre-revenue biopharmaceutical firm developing medicines for cancer, cardiovascular, and neurodegenerative disorders. It operates through acquired generic drug portfolios, biosimilar biologics platforms, and proprietary gene therapies (Klotho protein).
Recent Corporate Action: On June 21, 2024, the Company completed a reverse merger with Redwoods Acquisition Corp. and changed its legal name to Klotho Neurosciences, Inc. effective July 24, 2024.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Balance Sheet (Sept 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,959,426) | $(4,083,109) | N/A |
| Operating Expenses | $2,870,932 | $3,688,584 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $50,895 |
| Total Assets | N/A | N/A | $2,464,199 |
| Total Liabilities | N/A | N/A | $1,003,628 |
| Stockholders' Equity | N/A | N/A | $1,460,571 |
| Accumulated Deficit | N/A | N/A | $(8,495,536) |
| Net Cash Used in Operating Activities | N/A | $(2,002,358) | N/A |
| Net Cash Provided by Financing Activities | N/A | $2,173,942 | N/A |
Material Changes vs. Prior Period
- Expense Surge: Operating expenses for the nine months ended September 30, 2024, increased to $3.69 million from $0.52 million in the prior year period. This 608% increase was primarily driven by share-based compensation ($1.99 million) and professional fees related to the business combination.
- Net Loss Expansion: Net loss for the nine months ended September 30, 2024, widened to $4.08 million compared to $0.58 million in the same period in 2023.
- Debt Conversion: During the quarter, investors converted convertible promissory notes totaling approximately $4.01 million (principal and interest) into 4.05 million shares of common stock, significantly reducing debt obligations.
- Capital Structure: Following the June 2024 merger, the Company issued shares to ANEW stockholders and PIPE investors, increasing outstanding shares from approximately 15.1 million to 19.9 million.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has expressed substantial doubt about the Company's ability to continue as a going concern for twelve months. With only ~$51,000 in cash and an accumulated deficit of ~$8.5 million, the Company requires additional equity or debt financing to continue operations.
- NASDAQ Compliance Issues:
- Market Value: Received notice of non-compliance with minimum Market Value of Publicly Held Shares ($15M) and Market Value of Listed Securities ($50M) requirements. Deadline to regain compliance: February 12, 2025.
- Bid Price: Received notice of non-compliance with the $1.00 minimum bid price requirement. Deadline to regain compliance: April 14, 2025.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of September 30, 2024, citing material weaknesses due to inadequate accounting resources and lack of segregation of duties.
- Subsequent Financing: On November 14, 2024, the Company signed a $1.2 million convertible promissory note with Austria Capital LLC (net proceeds $1.0 million) to be closed by November 22, 2024.
- Contingent Consideration: Up to 5 million additional shares may be issued to former ANEW stockholders if specific stock price milestones ($12.50, $15.00, $20.00) are met within the next three to five years.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $50,895 cash balance against monthly burn rates and the status of the $1.2 million November financing.
- NASDAQ Status: Monitor the Company's progress toward meeting the $15M/$50M market value and $1.00 bid price requirements to avoid delisting.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in financial reporting and internal controls.
- Dilution Risk: Review the impact of the 5 million contingent shares and the recent issuance of shares for debt conversion on existing shareholder equity.
- Revenue Timeline: Confirm the projected timeline for commercializing the generic drug and biosimilar platforms, as the Company currently has zero revenue.